Washington: A groundbreaking study has revealed that people with diabetes who use weight-loss jabs, such as Saxenda, Wegovy, and Mounjaro, experience a reduced risk of 42 health conditions, including psychotic disorders, infections, and dementia.
The research, which is the most comprehensive of its kind, compared health outcomes between individuals with diabetes who received typical care and those who used GLP-1 receptor agonists (GLP-1RAs) like liraglutide, semaglutide, and tirzepatide.
Health Benefits
The results showed that those on GLP-1RAs had a significantly lower risk for conditions like opioid-use disorders (13%), bulimia (19%), Schizophrenia and Psychotic disorders (18%), suicidal ideation and attempts (10%), Alzheimer’s disease (12%), and bacterial infections (12%). However, the medications were also associated with an increased risk of 19 conditions, including abdominal pain, nausea, vomiting, low blood pressure, and kidney stones.
While the study focused on diabetes patients, researchers suggest that the benefits could also apply to individuals using these jabs for obesity treatment.
Dr. Ziyad Al-Aly, a co-author of the study, mentioned that, “There is no biologic or clinical reason to think that the beneficial and risk profiles would be very different in people without diabetes,” though he cautioned that those without obesity might not experience the full range of benefits.
Study Overview and Methodology
The study analysed records from the US Department of Veterans Affairs, tracking 215,970 diabetes patients using GLP-1RAs and 1,203,097 others receiving only usual care. Participants were followed for a median of about 3.5 years, with an average body mass index above the obesity threshold.
The study aimed to map the landscape of benefits and risks of these medications, which also showed that GLP-1RAs could be associated with lower risks for conditions like chronic kidney disease, clotting disorders, and others.
The researchers noted some surprising findings, such as the reduced risk of infections, which requires further study. Additionally, while weight loss may reduce stress on weight-bearing joints, the study found an increased risk of arthritis, possibly due to decreased muscle mass from rapid weight loss.
Broader Implications
This research is not the first to suggest GLP-1RAs could offer a host of health benefits, and scientists are already investigating their potential in treating conditions such as addiction and dementia.
In conclusion, the research highlights the significant potential of GLP-1RA medications, not only in managing diabetes and obesity but also in reducing the risk of various health conditions.
While further studies are needed to understand the long-term effects and the mechanisms behind these benefits, the findings pave the way for these treatments to be considered for a broader range of health issues, offering hope for improved health outcomes in individuals beyond those with diabetes.
RELATED POST | Experts call for redefining Obesity to improve Diagnosis and Care
